ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
12-O-Tetradecanoylphorbol-13-Acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder

This study has been completed.
Study NCT00004058.   Last updated on November 16, 2008.   Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:
1 Conditions listed in this trial
Leukemia
Lymphoma
Myelodysplastic Syndromes
Precancerous/Nonmalignant Condition
2 Additional conditions recognized in this trial
Bone Marrow Diseases
Disease
Multiple Myeloma
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Neoplasms, Plasma Cell
Precancerous Conditions
Preleukemia
Syndrome
3 More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Pathologic Processes
Vascular Diseases
4 Interventions listed in this trial
tetradecanoylphorbol acetate
5 Sponsors listed in this trial
Cancer Institute of New Jersey
National Cancer Institute (NCI)




Links to all studies - primarily for crawlers